Evotec SE ADR(EVO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 15 at 4:01 AM ET (Korea 9/15 17:01)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.65 | Insider Own | 5.17% | Shs Outstand | 355.2M | Perf Week | -9.68% |
| Market Cap | 0.60B | Forward P/E | - | EPS next Y | 75.31% | Insider Trans | - | Shs Float | 336.8M | Perf Month | -16.83% |
| Enterprise Value | 0.61B | PEG | - | EPS next Q | -0.27 | Inst Own | 0.91% | Short Float | 0.03% | Perf Quarter | -38.24% |
| Income | -0.23B | P/S | 0.71 | EPS this Y | -119.83% | Inst Trans | 1.79% | Short Ratio | 1.59 | Perf Half Y | -27.27% |
| Sales | 0.84B | P/B | 0.78 | EPS next 5Y | - | ROA | -11.74% | Short Interest | 0.09M | Perf YTD | -45.45% |
| Book/sh | 2.14 | P/C | 1.12 | EPS past 3/5Y | 14.3% - | ROE | -26.25% | 52W High | -60.66% ($4.27) | Perf Year | -51.59% |
| Cash/sh | 1.5 | P/FCF | - | Sales past 3/5Y | 4.05% 9.27% | ROIC | -18.65% | 52W Low | -2.33% ($1.72) | Perf 3Y | -86.3% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -35.64% | Gross Margin | 10.47% | Volatility(W/M) | 1.8% 2.07% | Perf 5Y | -93.57% |
| Dividend TTM | - | EV/Sales | 0.73 | Sales Y/Y TTM | -0.86% | Oper. Margin | -18.62% | ATR (14) | 0.07 | Perf 10Y | -31.36% |
| Dividend Ex-Date | 2019/1/11 | Quick Ratio | 2.21 | EPS Q/Q | -10.02% | Profit Margin | -27.53% | RSI (14) | 30.03 | Recom | 2.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.33 | Sales Q/Q | -14.05% | SMA20 | -10.4% ($1.88) | Beta | 1.97 | Target Price | $2.75 |
| Payout | - | Debt/Eq | 0.71 | Earnings | 2026/8/13 | SMA50 | -17.53% ($2.04) | Rel Volume | 0.66 | Prev Close | $1.73 |
| Employees | 4553 | LT Debt/Eq | 0.62 | EPS/Sales Surpr. | -275.25% 0.91% | SMA200 | -40.07% ($2.8) | Avg Volume(3M) | 0.06M | Price | $1.68 |
| IPO | 2004/2/5 | Option/Short | No/Yes | Trades | 251 | Volume | 37,704 | Change | -2.89% |
Company
EVO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Evotec (EVO) is a global drug discovery and development partner based in Germany. It is an integrated contract research organization (CRO) that provides end-to-end services—from drug discovery through preclinical development—on behalf of pharmaceutical and biotech clients, and it also operates a contract manufacturing platform for biopharmaceuticals. The company covers a wide range of modalities, from small-molecule compounds to biotherapeutic treatments.
Over the past 1 year, on the lower side
61% below its 1-year high.
EVO has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -119.8% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -86.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 0.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
WCMI 0.01%
IEUS 0.00%
GWX 0.00%
DISV 0.00%
SCHC 0.00%It ranks #4 in the industry
Based on market cap of $597M.
EVO $597M PER -
TAK $59B PER -
TEVA $45B PER 64.5
HLN $41B PER 19.3
FAQ
What kind of company is EVO?
EVO belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of EVO?
The market cap of EVO is approximately $597M, ranking 3,077 within its sector.
What is the 52-week high and low for EVO?
EVO has recorded a 52-week high of $4.27 and a low of $1.72.
